1. 1399PImpact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Peters, S; Shaw, A T; Besse, B; Felip, E; Solomon, B J; Soo, R A; Bearz, A; Gadgee, S M; Lin, C-C; Kao, S; Seto, T; Masters, E T; Abbattista, A; Clancy, J S; Thurm, H; Reisman, A; Camidge, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗